期刊文献+

质子泵抑制药不合理使用干预效果评价 被引量:4

Evaluation of Intervention Effect in Unreasonable Proton Pump Inhibitors Use
下载PDF
导出
摘要 目的:评价质子泵抑制药(PPIs)不合理使用的干预效果。方法:抽取2013年1~12月使用PPIs的门诊处方和住院病历,统计PPIs使用率、注射剂使用率和不合理使用率,并与2011年1~12月的数据进行比较。结果:干预后,我院门诊及住院PPIs使用率分别由7.38%和34.86%降至4.36%和20.88%(P〈0.05);门诊处方注射剂使用率无明显变化,住院患者注射剂使用率由82.97%降至71.14%(P〈0.05)。门诊及住院患者PPIs不合理使用率分别由5.67%和67.08%降至3.15%和33.75%(P〈0.05)。结论:行政及技术干预在PPIs的合理使用中起着非常重要的作用。 Objective:To evaluate the effects of intervention of the administrative and technical interventions in unreasonable proton pump inhibitors (PPIs) use. Methods: To extract the prescriptions of outpatient and the medical recards of hospitalization from January to December in 2013 ,anc[ count the use rate of PPIs and use rate of PPIs injection and unreasonable utilization of PPIs, and to compare the data from that January to December in 2011. Results:The use rate of Outpatients and inpatients of PPIs reduce from 7.38% and 34.86% before intervention to 4.36% and 20.88% after intervention respectively. The use rate of PPIs injection of outpatients have not been significant change and the use rate of PPIs injection of inpatients reduce from 82.97% to 71.14%. The unreasonable usage rate of outpatients and inpatient of PPIs reduce from 5.67% and 67.08% to 3.15% and 33.75% respectively. Conclusion.The administrative and technical intervention measures plays an very important role in the rational PPIs use.
出处 《药物流行病学杂志》 CAS 2014年第10期612-615,共4页 Chinese Journal of Pharmacoepidemiology
基金 宜春市科技计划(编号:JXYC2011KSB034)
关键词 质子泵抑制药 干预 注射剂 合理用药 Proton pump inhibitors Intervention Injection Rational drug use
  • 相关文献

参考文献10

二级参考文献150

共引文献123

同被引文献87

  • 1Bez C, Perrottet N, Zingg T, et al. Stress ulcer prophylaxis in non-critically ill patients:a prospective evaluation of current practice in a general surgery department[ J ]. Journal of Eval- uation in Clinical Practice,2013,19(2) :374-378. 被引量:1
  • 2Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35. 被引量:1
  • 3Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323-2330. 被引量:1
  • 4L?drup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515-522. 被引量:1
  • 5Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy. 2011;100:148-156. 被引量:1
  • 6Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012;166:1684-1693. 被引量:1
  • 7Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses. 2011;77:451-452. 被引量:1
  • 8Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013;12:709-716. 被引量:1
  • 9Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O'Corragain OA, Korpaisarn S, Erickson SB. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237-1241. 被引量:1
  • 10Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2012;9:322-326. 被引量:1

引证文献4

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部